Centre Cardiologique D Evecquemont
- Address
- 2 Rue Des Carrieres, 78740 Evecquemont, France
Cardiovascular Diseases
At Centre Cardiologique D Evecquemont, the clinical trial portfolio focuses on cardiovascular diseases, with research centered on serious heart and blood vessel conditions that affect long-term health and recovery. The studies are designed to evaluate new treatment approaches and improve outcomes for people living with complex cardiometabolic risk factors.
- Type 2 diabetes and hypertension in people with established cardiovascular disease
- ST-elevation myocardial infarction and related acute coronary syndrome care
- Testing a new therapy strategy to reduce major cardiovascular events and heart failure complications
- Assessing tools aimed at improving treatment delivery for microvascular injury after a heart attack
Overall, the site is contributing to research that seeks both better prevention of cardiovascular complications and improved care for patients recovering from acute cardiac events.
Cardiometabolic Risk and Heart Failure Prevention
This research area brings together type 2 diabetes, high blood pressure, and cardiovascular disease, reflecting a strong focus on patients at elevated risk of heart failure and other major events. The trial work is aimed at understanding whether new treatment combinations can offer better protection than current approaches.
- Reducing the risk of cardiovascular death
- Preventing heart failure hospitalization and urgent heart failure visits
- Evaluating treatment effectiveness in people with combined metabolic and cardiovascular conditions
The studies at this French site highlight practical questions about how to improve outcomes for patients with overlapping metabolic and cardiac disease.
Acute Coronary Syndrome and Microvascular Injury
Another key line of investigation at Centre Cardiologique D Evecquemont involves acute coronary syndrome, especially ST-elevation myocardial infarction complicated by microvascular obstruction. The research is exploring whether a new delivery platform can help bring therapeutic agents directly to the affected heart tissue and support recovery after a major cardiac event.
- STEMI and post-infarction microvascular damage
- Improving delivery of therapies to the coronary circulation
- Identifying markers that may help show whether treatment is working
This work combines treatment development with efforts to better understand and measure healing after severe heart attacks.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 3 by active trials.
- 1Boehringer Ingelheim Espana S.A.1active
lock +2 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 978 other sites in France
Therapeutic Area Benchmark — France
Select a therapeutic area to compare against other sites in France.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: France
Market Share
Country: France
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Centre Cardiologique D Evecquemont
lock Showing 1 of 2 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Evaluation of Intracoronary Tirofiban and Adenosine via CoFI System for the Treatment of Microvascular Obstruction in Patients with ST-Elevation Myocardial Infarction | Corflow Therapeutics AG | Phase II | Recruiting | Jul 2026 | — |
IMP list
lock Showing 1 of 3 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Adenosine | 1 | Unknown | 2026-07-26 | 2026-07-26 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.